Abbvie Inc
Abbvie Inc (ABBV) Covered Calls
Abbvie Inc trades in the Drug Manufacturers - General industry with an IV Rank of 23.61%, low versus the past year. ABBV's highest covered call setup is the $315.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 6.77% out of the money with 7 days to expiration, a 6.80% return until expiration, and a 354.36% theoretical annualized return. Across the setups shown, annualized returns run from 189.82% to 354.36% at strikes between $305.00 and $360.00, with 7 to 35 days to expiration, as of Nov 13, 2026.
Read more
Running ABBV covered calls helps you generate income from Abbvie Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABBV covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ABBV stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABBV covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABBV covered call is worth writing.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
| 2026-11-20 | 7 | 315.00 | 6.77 | 0.08 | 0.25 | 2005.00 | 6.80 | 354.36 | -0.03 | +0.04 | 616 | 0.17 |
| 2026-11-20 | 7 | 310.00 | 5.07 | 0.28 | 0.48 | 1525.00 | 5.17 | 269.52 | -0.09 | +0.08 | 1,542 | 0.20 |
| 2026-11-27 | 14 | 325.00 | 10.16 | 0.01 | 0.35 | 2998.00 | 10.16 | 264.93 | -0.00 | +0.03 | 39 | 0.34 |
| 2026-12-18 | 35 | 360.00 | 22.02 | 0.02 | 0.29 | 6499.00 | 22.03 | 229.72 | -0.01 | +0.02 | 20 | 0.27 |
| 2026-11-20 | 7 | 307.50 | 4.23 | 0.24 | 0.73 | 1271.00 | 4.31 | 224.63 | -0.08 | +0.11 | 181 | 0.49 |
| 2026-11-27 | 14 | 320.00 | 8.46 | 0.10 | 0.66 | 2507.00 | 8.50 | 221.54 | -0.03 | +0.06 | 55 | 0.56 |
| 2026-12-04 | 21 | 330.00 | 11.85 | 0.13 | 0.25 | 3510.00 | 11.90 | 206.78 | -0.04 | +0.03 | 8 | 0.12 |
| 2026-11-27 | 14 | 317.50 | 7.62 | 0.05 | 0.43 | 2252.00 | 7.63 | 199.01 | -0.02 | +0.05 | 0 | 0.38 |
| 2026-12-18 | 35 | 350.00 | 18.63 | 0.10 | 0.37 | 5507.00 | 18.67 | 194.66 | -0.03 | +0.03 | 89 | 0.27 |
| 2026-11-20 | 7 | 305.00 | 3.38 | 0.77 | 1.00 | 1074.00 | 3.64 | 189.82 | -0.26 | +0.17 | 237 | 0.23 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryDrug Manufacturers - General
- SectorHealthcare
- IV Rank23.61% Low
- Market cap (M$)521,500
- 52 weeks high-2.61%
- 52 weeks low54.67%
- Analyst recommendationBuy
1.57 - Target price$314.81
6.70% above the current stock price - Dividend—
- Payout ratio281.66%
- Earnings date2027-02-03
- P/E50.78
- Future P/E18.14
- EPS (ttm)5.81
- EPS growth next 5 years21.77%
As of Nov 13, 2026